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Poster Session II S3115x104 CD3 cells/kg, no additional GvHD prophylaxis was adminis-
tered. The median age at transplant was 9.9 years (range, 2.9 to 21.6)
and median follow-up 44 months post SCT (range, 13 to 102). Me-
dian CD34+ cell dose infused was 1.14x107/kg (range, 0.49-
6.83x107/kg) and median CD3+ T-cell dose was 3.08x104/kg (range,
1.8x104-1.6x105/kg). The rate of donor engraftment was 82.4% – 3
patients failed to achieve initial donor engraftment but did so after
receiving subsequent haploidentical SCT. Eleven of 17 (65%) pa-
tients received additional T-cell therapies post SCT (donor lympho-
cytes for mixed chimerism, cytotoxic T-lymphocyte therapy or
planned T-cell addback strategies to re-establish T-cell immune re-
constitution) and 2 received additional CD34+ cells for poor graft
function. Two-year disease-free survival for these children is
60.5%. Of the 5 children who died, 2 died of relapse and 3 of treat-
ment-related causes, primarily infection. One patient with p53 mu-
tation developed secondary MDS 2 years post SCT and is alive
with disease. In conclusion, while this data is preliminary, haploi-
dentical transplants using in vivoT-cell depletion with alemtuzumab
and ex vivo T-cell depletion with CD34+ selection offers promising
clinical results in children with ALL in CR1 or CR2.With the addi-
tion of new clinical immunotherapy trials post SCT, we hope to
achieve even higher survival with decreased relapse and deaths
related to viral infection.433
LEUKEMIA RELAPSE: DETECTED BY BONE MARROW CHIMERISM ANAL-
YSIS BUT MISSED BY PERIPHERAL BLOOD ENGRAFTMENT MONITORING
ALONE
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Chimerism analysis is frequently used for the surveillance of en-
graftment especially post allogenic stem cell transplantation for ma-
lignant hematopoietic diseases (HSCT). The most common
method, PCR-based short tandem repeats (STR) analysis, offers
high sensitivity and specificity in monitoring graft chimerism after
HSCT. Multiple panels of STRs have been developed for use on
bone marrow aspirate (BMA) and peripheral blood (PB). In accor-
dance with 2001workshop (tandemmeeting ASBMT) recommenda-
tions, PB has been widely used to serially characterize the
hematologic course of engraftment and/or occurrence. In the pres-
ent study, we evaluated the value of STR assay for surveillance of
acute leukemia relapse in patients with established HSCT engraft-
ments. A total of 87HSCT recipients with clinically stable and estab-
lished engraftment were retrospectively analyzed. All cases had been
monitored by serial STR analysis using both BMA and PB samples
with a commercially available panel of ten markers (D3S1358-
vWA-FGA-AMEL-D8S1179-D21S11-D18S51-D5S818-D13S317-
D7S820). Additionally, patients’ bone marrow biopsies were also
reviewed at the time of BMA STR analysis. Among these 87 patients,
70 patients sustained complete remission and their PB and BMA
showed 100% donor origin in the STR assays. There were 17 pa-
tients who had relapse ranging from 81 days to 442 days after trans-
plantation, as documented by BM biopsy and/or clinical
presentation. All of these 17 patients showed a mixed chimerism
on BMA STR assay at the same time BM biopsy showed relapse.
In these relapse patients, the percentage of donor origin were lower
in granulocytes than in mononuclear cells (52.468% vs 84.564%; p
\ 0.05) while 3 patients showed mixed chimerism in the mononu-
clear cells only. In contrast, there were 4 out of the 17 patients
with negative PB STR assays in the immediate time period around
which the BMA STR analysis became positive. Interestingly, in
one patient when BM STR assay showed mixed chimerism, the
BM biopsy obtained at the same time was inconclusive for relapse.
Our findings indicated that caution should be taken when using
PB STR solely to monitor leukemia relapse because it maymiss early
recurrence. This may delay a change in treatment. Second, BM STR
assay is a very sensitive method in HSCT surveillance even in pa-
tients with a negative or inconclusive BM biopsy. At last, mononu-
clear cells are more sensitive in detecting mixed chimerism than
granulocytes.434
FACILE DOUBLE CORD TRANSPLANT SCREENING AND MONITORING
Bost, D.A., McLaughlin, I.J., Beckert, S. Celera, Alameda, CA
STR-PCR is limited in its utility for screening and monitoring of
donors and recipients in double cord transplants, given its inherent
lack of sensitivity and the presence of stutter artifacts which obscure
potentially informative alleles. If markers are identified for each in-
dividual in a double cord transplant, the manual execution of the al-
gorithm for quantification of individuals is quite time-consuming.
To simplify these analyses, we designed a multiplexed system of
RUO assays and software enabling instantaneous marker identifica-
tion and quantification post-PCR.
We employ a panel of 34 quantitative PCR research assays to bi-
allelic indels in which the probability of finding at least one informa-
tive marker is. 99.9% in unrelated individuals (Caucasian, African,
Japanese, Amerindian populations). The probability of finding at
least one informative marker in siblings is . 99%, 98%, 98% and
97% for European Caucasian, Japanese, Amerindian and African
populations, respectively.
Results: Each research assay was tested using simulated DNA mix-
tures at 0.05%, 0.1%, 0.2% and 0.4% minor component for 250 ng
of input genomic DNA. Each assay detected the 0.05% minor com-
ponent mixture. The limitation at this low sensitivity is input copy
number. In addition, each of the assays in the panel was able to de-
tect, with statistical significance (p\ 0.05), the 2-fold change be-
tween the 0.1% and 0.2% minor component mixtures. Multiple
assays tested on the same mixtures gave highly reproducible results.
We also developed research use software allowing for facile analysis
of marker screening and post-transplant monitoring quantification.
Results are generated with one click of a mouse button.
Conclusions: Use of this research qPCR system for screening and
engraftment monitoring of double cord transplants would enable
rapid identification of informative markers and several logs increase
in sensitivity over the current standard practices. The ability to de-
tect early changes in increasing mixed chimerism, with greater accu-
racy and precision, allows for more effective research into the
potential benefits of earlier detection of clinically significant events,
such as relapse or rejection.435
ATTEMPTS TO OPTIMIZING THE OUTCOMES OF ALLOGENEIC HEMATO-
POIETIC CELL TRANSPLANTATION IN OLDER PATIENTS ($60 YEARS)
WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME
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Using a non-myeloablative (NMA) regimen [Fludarabine 125mg/
m2 and total body irradiation (TBI) 200cGY], we previously reported
the feasibility of allogeneic hematopoietic cell transplantation
(HCT) in older patients (n 5 24) with AML/MDS using matched
sibling donors (MSD) (Gupta et al, 2005, BBMT). GvHD prophy-
laxis was with Cyclosporine (CsA) (42 days) and Mycophenolate
(MMF) for (30 days); CsA was tapered at 42 days in the absence of
GvHD.While survival was reasonable; 2 main issues were identified:
early relapse and severe chronic GvHD in some patients. To address
these issues, we added IV Busulphan (3.2mg/KBWIV daily x 2 days)
to Flu/TBI regimen, and increased the duration of GvHD prophy-
laxis with CsA from 42 days to 100 days. We compare the outcomes
of these 2 sequential strategies: Cohort 1 (n 5 24, treated 2000-
2004), less intense NMA regimen and shorter GvHD prophylaxis;
Cohort 2 (n 5 31, treated 2005-2009), more intense NMA regimen
and longer GvHD prophylaxis. The median age of all study patients
(n5 55) was 63 years (range 60-71); 47 (86%) had AML in CR1 (n5
33) or CR2 (n5 14), and 8 (14%) hadMDS; 22% had severe comor-
bidities; and 29% had adverse risk cytogenetics. Baseline character-
istics were well-matched in the two cohorts, except cohort 2 had 6
(19%) patients with unrelated donors HCT. Median follow-up of
survivors in cohort 1 and 2 was 72 months (13-102) and 31 months
(16-49), respectively. A significantly higher proportion of patients
had grade $ 2 stomatitis (Bearman Criteria) in the later cohort
